Avalo Therapeutics, Inc.
NASDAQ:AVTXBiotechnology
-$0.34 today
- Market cap
- $387.41M
- Beta
- 0.82
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$4.21
Volume 1.58M
Average 1.61M
AVTX EBITDA Margin
EBITDA as a percentage of revenue.
Avalo Therapeutics, Inc.NASDAQ: AVTX
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin not reported for Q1 FY2026
Over 3 fiscal years it narrowed by 131573.1 pp.
Context
- EBITDA Margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 12 analysts of -3157.2% for the fiscal year ending Dec 2026, up from -131779.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- —— QoQ
- Last fiscal yearDec 2025
- -131779.7%-123878.1 pp YoY
- LTMMar 2026
- -142957.6%-159600.9 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -131779.7%
- Year-over-year change
- -123878.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -131779.7% | -123878.1pp |
| FY2024 | 2024-12-31 | -7901.6% | -6691.3pp |
| FY2023 | 2023-12-31 | -1210.3% | -1003.7pp |
| FY2022 | 2022-12-31 | -206.6% | +1284.6pp |
| FY2021 | 2021-12-31 | -1491.2% | — |
EBITDA Margin vs competitors
How AVTX compares with its peers on the latest reported figures
- AVTX's LTM Mar 2026 EBITDA Margin of -142957.6% is the 6th highest of the 7 companies compared; the peer median is -213.6%.
- Its year-over-year change of -159600.9 pp is the lowest of 5, against a peer median of -296.9 pp.
- Over three fiscal years its change of -131573.1 pp compares with a peer median of +303.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 41.2% | — | +616.4 pp | |
| LTM Mar 2026 | 25.2% | +93.4 pp | +1052.7 pp | |
| LTM Jun 2026 | -117.7% | -51.9 pp | -9.6 pp | |
| LTM Sep 2026 | -309.5% | — | — | |
| LTM Mar 2026 | -843.9% | -542.0 pp | -540.2 pp | |
| LTM Mar 2026 | -142957.6% | -159600.9 pp | -131573.1 pp | |
| LTM Mar 2026 | -144435.8% | -111246.8 pp | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding AVTX) | -213.6% | -296.9 pp | +303.4 pp | |
Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.4M | 18.05M | 1.92M | 441K | 59K |
| Cost of Revenue | 1.49M | 3.43M | 1.28M | (366K) | 0 |
| Gross Profit | 3.91M | 14.62M | 640K | 807K | 59K |
| Gross Margin | 72.4% | 81.0% | 33.3% | 183.0% | 100.0% |
| Research & Development | 59.84M | 31.31M | 13.78M | 52.08M | 50.08M |
| Selling, General & Admin | 24.66M | 20.71M | 10.3M | 17.24M | 22.9M |
| Operating Expenses | 86.04M | 52.06M | 27.99M | 69.32M | 72.98M |
| Depreciation & Amortization | 1.66M | 166K | 158K | 169K | 344K |
| EBITDA | (80.5M) | (37.29M) | (23.29M) | (34.85M) | (77.75M) |
| EBITDA Margin | -1491.2% | -206.6% | -1210.3% | -7901.6% | -131779.7% |
| Operating Income | (82.13M) | (37.44M) | (27.35M) | (68.51M) | (72.93M) |
| Operating Margin | -1521.6% | -207.4% | -1421.6% | -15535.6% | -123601.7% |
| Interest Income | 0 | 0 | 0 | 3.32M | 4.35M |
| Interest Expense | 2.39M | 4.17M | 3.42M | 0 | 0 |
| Other Income / Expenses | (2.41M) | (4.19M) | (4.18M) | 33.5M | (5.17M) |
| Income Before Tax | (84.55M) | (41.63M) | (31.53M) | (35.02M) | (78.09M) |
| Pre-Tax Margin | -1566.2% | -230.6% | -1638.8% | -7939.9% | -132362.7% |
| Income Tax Expense | (196K) | 28K | 14K | 114K | 165K |
| Net Income | (84.38M) | (41.66M) | (31.54M) | (35.13M) | (78.26M) |
| Net Margin | -1563.1% | -230.8% | -1639.5% | -7965.8% | -132642.4% |
| EPS (Basic) | (2,330.66) | (1,062.65) | (113.58) | (4.32) | (5.84) |
| EPS (Diluted) | (2,330.66) | (1,062.65) | (113.58) | (3.26) | (5.84) |
| Weighted Avg Shares | 36.19K | 39.2K | 277.73K | 8.13M | 13.4M |
| Weighted Avg Shares (Diluted) | 36.19K | 39.2K | 277.73K | 10.78M | 13.4M |
Avalo Therapeutics, Inc.
NASDAQ:AVTX
Intrinsic Alpha fair value
Locked
Current Price
$6.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.